EP3930747A4 - Immunotherapeutic combination for treating cancer - Google Patents

Immunotherapeutic combination for treating cancer Download PDF

Info

Publication number
EP3930747A4
EP3930747A4 EP20763489.0A EP20763489A EP3930747A4 EP 3930747 A4 EP3930747 A4 EP 3930747A4 EP 20763489 A EP20763489 A EP 20763489A EP 3930747 A4 EP3930747 A4 EP 3930747A4
Authority
EP
European Patent Office
Prior art keywords
treating cancer
immunotherapeutic combination
immunotherapeutic
combination
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20763489.0A
Other languages
German (de)
French (fr)
Other versions
EP3930747A1 (en
Inventor
Jonathan Zalevsky
Agnete Brunsvik Fredriksen
Mads Axelsen
Karoline SCHJETNE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nykode Therapeutics ASA
Nektar Therapeutics
Original Assignee
Nykode Therapeutics ASA
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nykode Therapeutics ASA, Nektar Therapeutics filed Critical Nykode Therapeutics ASA
Publication of EP3930747A1 publication Critical patent/EP3930747A1/en
Publication of EP3930747A4 publication Critical patent/EP3930747A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
EP20763489.0A 2019-02-27 2020-02-27 Immunotherapeutic combination for treating cancer Withdrawn EP3930747A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962811459P 2019-02-27 2019-02-27
US201962825487P 2019-03-28 2019-03-28
US201962838180P 2019-04-24 2019-04-24
US201962881832P 2019-08-01 2019-08-01
PCT/US2020/020224 WO2020176797A1 (en) 2019-02-27 2020-02-27 Immunotherapeutic combination for treating cancer

Publications (2)

Publication Number Publication Date
EP3930747A1 EP3930747A1 (en) 2022-01-05
EP3930747A4 true EP3930747A4 (en) 2023-04-05

Family

ID=72238533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20763489.0A Withdrawn EP3930747A4 (en) 2019-02-27 2020-02-27 Immunotherapeutic combination for treating cancer

Country Status (4)

Country Link
EP (1) EP3930747A4 (en)
JP (1) JP2022521792A (en)
CN (1) CN113631185A (en)
WO (1) WO2020176797A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096735A (en) 2020-05-01 2023-05-09 耐考德治疗股份有限公司 Prevention and treatment of coronavirus B
CA3212592A1 (en) 2021-03-26 2022-09-29 Agnete Fredriksen Therapeutic combination for treating cancer
EP4333881A1 (en) 2021-05-03 2024-03-13 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
KR20240019135A (en) 2021-05-10 2024-02-14 니코데 테라퓨틱스 에이에스에이 Co-expression of constructs and immunostimulatory compounds
EP4337251A1 (en) 2021-05-10 2024-03-20 Nykode Therapeutics ASA Tolerance-inducing constructs and composition and their use for the treatment of immune disorders
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
JP2024518463A (en) 2021-05-10 2024-05-01 ナイコード セラピューティクス アルメン アクスイェ セルスカプ Co-expression of constructs and immunoinhibitory compounds
WO2022238363A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases
WO2022238395A1 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Tolerance-inducing constructs and compositions and their use for the treatment of immune disorders
WO2023079001A1 (en) 2021-11-03 2023-05-11 Nykode Therapeutics ASA Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of diseases caused by sars-cov-2
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170216403A1 (en) * 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
WO2018089669A2 (en) * 2016-11-10 2018-05-17 Nektar Therapeutics Immunotherapeutic tumor treatment method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515588A (en) * 2015-05-26 2018-06-14 アドバクシス， インコーポレイテッド Immunotherapy based on personalized delivery vectors and their use
CA3008437A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
SG11201808196UA (en) * 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
WO2018039567A1 (en) * 2016-08-25 2018-03-01 Nantomics, Llc Immunotherapy markers and uses therefor
EP3641803A2 (en) * 2017-06-21 2020-04-29 Transgene Personalized vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170216403A1 (en) * 2014-08-12 2017-08-03 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
WO2018089669A2 (en) * 2016-11-10 2018-05-17 Nektar Therapeutics Immunotherapeutic tumor treatment method

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELIZABETH I. BUCHBINDER ET AL: "CTLA-4 and PD-1 Pathways : Similarities, Differences, and Implications of Their Inhibition", AMERICAN JOURNAL OF CLINICAL ONCOLOGY (CANCER CLINICAL TRIALS)., vol. 39, no. 1, 1 February 2016 (2016-02-01), US, pages 98 - 106, XP055393184, ISSN: 0277-3732, DOI: 10.1097/COC.0000000000000239 *
See also references of WO2020176797A1 *
XUE WEI ET AL: "SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors", ONCOTARGET, vol. 7, no. 50, 13 December 2016 (2016-12-13), pages 83088 - 83100, XP093025668, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347755/pdf/oncotarget-07-83088.pdf> DOI: 10.18632/oncotarget.13070 *

Also Published As

Publication number Publication date
JP2022521792A (en) 2022-04-12
CN113631185A (en) 2021-11-09
WO2020176797A1 (en) 2020-09-03
EP3930747A1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
EP3930747A4 (en) Immunotherapeutic combination for treating cancer
EP3781564A4 (en) Compounds for the treatment of cancer
EP3678663A4 (en) Combination therapy for treating cancer
EP3892282A4 (en) Combination for treating cancer
EP3706770A4 (en) Immunotherapeutic combination for treating cancer
EP3836909A4 (en) Biomarkers for cancer therapy
IL287907A (en) Methods for treating cancer
GB201903546D0 (en) Cancer treatment
EP3820461A4 (en) Method for treating cancer
EP3946456A4 (en) Targeted synergistic cancer immunotherapy
SG11202010528XA (en) Combinations for treating cancer
EP3796891A4 (en) Therapeutic constructs for treating cancer
IL287652A (en) Cancer treatment
IL285807A (en) Immunotherapy for the treatment of cancer
EP3922251A4 (en) Cancer immunotheraphy adjuvant
EP3755711A4 (en) Immunotherapeutic composition for the treatment of cancer
IL289006A (en) Combination cancer immunotherapy
EP3755341A4 (en) Combination therapies for treating cancers
IL285466A (en) Cancer treatment
EP3962919A4 (en) Compounds for treating cancer
EP4025204A4 (en) Cancer immunotherapy
EP3990022A4 (en) Anti-cd33 antibodies for treating cancer
EP3969012A4 (en) Methods concerning ongoing treatment for cancer
EP3894561A4 (en) Methods for treating cancer
GB201909468D0 (en) Compounds for treating cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NYKODE THERAPEUTICS ASA

Owner name: NEKTAR THERAPEUTICS

A4 Supplementary search report drawn up and despatched

Effective date: 20230306

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20230228BHEP

Ipc: C12N 7/00 20060101ALI20230228BHEP

Ipc: C07K 16/28 20060101ALI20230228BHEP

Ipc: A61K 39/00 20060101AFI20230228BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20231003